Literature DB >> 24337602

Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.

Amey Bandekar1, Charles Zhu, Rohit Jindal, Frank Bruchertseifer, Alfred Morgenstern, Stavroula Sofou.   

Abstract

UNLABELLED: This study evaluates targeted liposomes loaded with the α-particle generator (225)Ac to selectively kill prostate-specific membrane antigen (PSMA)-expressing cells with the aim to assess their potential for targeted antivascular radiotherapy.
METHODS: In this study, PEGylated liposomes were loaded with (225)Ac and labeled with the mouse antihuman PSMA J591 antibody or with the A10 PSMA aptamer. The targeting selectivity, extent of internalization, and killing efficacy of liposomes were evaluated on monolayers of prostate cancer cells intrinsically expressing PSMA (human LNCaP and rat Mat-Lu cells) and on monolayers of HUVEC induced to express PSMA (induced HUVEC).
RESULTS: The loading efficiency of (225)Ac into preformed liposomes ranged from 58.0% ± 4.6% to 85.6% ± 11.7% of introduced radioactivity. The conjugation reactions resulted in approximately 17 ± 2 J591 antibodies and 9 ± 2 A10 aptamers per liposome. The average size of liposomes, 107 ± 2 nm in diameter, was not affected by conjugation or loading. LNCaP cells exhibit 2:1:0.5 relative PSMA expression, compared with MatLu and induced HUVEC, respectively, based on flow cytometry detecting association of the J591 antibody. J591-labeled liposomes display higher levels of total specific binding to all cell lines than A10 aptamer-labeled liposomes. Specific cell association of targeted liposomes increases with incubation time. Cytotoxicity studies demonstrate that radiolabeled J591-labeled liposomes are most cytotoxic, with median lethal dose values, after 24 h of incubation, equal to 1.96 (5.3 × 10(-5)), 2.92 × 10(2) (7.9 × 10(-3)), and 2.33 × 10(1) Bq/mL (6.3 × 10(-4) μCi/mL) for LNCaP, Mat-Lu, and induced HUVEC, respectively, which are comparable to the values for the radiolabeled J591 antibody. For A10 aptamer-labeled liposomes, the corresponding values are 3.70 × 10(1) (1.0 × 10(-3)), 1.85 × 10(3) (5.0 × 10(-2)), and 4.07 × 10(3) Bq/mL (1.1 × 10(-1) μCi/mL), respectively.
CONCLUSION: Our studies demonstrate that anti-PSMA-targeted liposomes loaded with (225)Ac selectively bind, become internalized, and kill PSMA-expressing cells including endothelial cells induced to express PSMA. These findings-combined with the unique ability of liposomes to be easily tuned, in terms of size and surface modification, for optimizing biodistributions-suggest the potential of PSMA-targeting liposomes encapsulating α-particle emitters for selective antivascular α radiotherapy.

Entities:  

Keywords:  anti-PSMA liposomes; antivascular α-particle radiotherapy; liposomal 225Ac

Mesh:

Substances:

Year:  2013        PMID: 24337602     DOI: 10.2967/jnumed.113.125476

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

1.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Authors:  Nikki A Thiele; Justin J Wilson
Journal:  Cancer Biother Radiopharm       Date:  2018-06-11       Impact factor: 3.099

2.  Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer.

Authors:  Hossein Jadvar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-11       Impact factor: 9.236

3.  Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

Authors:  Lingegowda S Mangala; Hongyu Wang; Dahai Jiang; Sherry Y Wu; Anoma Somasunderam; David E Volk; Ganesh L R Lokesh; Xin Li; Sunila Pradeep; Xianbin Yang; Monika Haemmerle; Cristian Rodriguez-Aguayo; Archana S Nagaraja; Rajesha Rupaimoole; Emine Bayraktar; Recep Bayraktar; Li Li; Takemi Tanaka; Wei Hu; Cristina Ivan; Kshipra M Gharpure; Michael H McGuire; Varatharasa Thiviyanathan; Xinna Zhang; Sourindra N Maiti; Nataliya Bulayeva; Hyun-Jin Choi; Piotr L Dorniak; Laurence Jn Cooper; Kevin P Rosenblatt; Gabriel Lopez-Berestein; David G Gorenstein; Anil K Sood
Journal:  JCI Insight       Date:  2016-10-20

Review 4.  Applications of aptamers in targeted imaging: state of the art.

Authors:  Casey A Dougherty; Weibo Cai; Hao Hong
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

5.  Anti-Prostate Cancer Activity of 8-Hydroxyquinoline-2-Carboxaldehyde-Thiosemicarbazide Copper Complexes by Fluorescent Microscopic Imaging.

Authors:  Fang Xie; Fangyu Peng
Journal:  J Fluoresc       Date:  2017-06-26       Impact factor: 2.217

Review 6.  Aptamer-based targeted therapy.

Authors:  Guizhi Zhu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-08-17       Impact factor: 15.470

7.  Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model.

Authors:  Jessie R Nedrow; Anders Josefsson; Sunju Park; Tom Bäck; Robert F Hobbs; Cory Brayton; Frank Bruchertseifer; Alfred Morgenstern; George Sgouros
Journal:  EJNMMI Res       Date:  2017-07-18       Impact factor: 3.138

Review 8.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

9.  Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.

Authors:  Wei Li; Zhongyun Liu; Chengxia Li; Ning Li; Lei Fang; Jin Chang; Jian Tan
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-16       Impact factor: 4.553

10.  Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.

Authors:  Vikas Prasad; Ingo G Steffen; Gerd Diederichs; Marcus R Makowski; Peter Wust; Winfried Brenner
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.